Abstract:Artemisinin-based combination therapy (ACT) is the mainstay of effective treatment of Plasmodium falciparum malaria. However, the long-term utility of ACTs is imperiled by widespread partial artemisinin resistance in Southeast Asia and its recent emergence in parts of East Africa. This underscores the need to identify chemotypes with new modes of action (MoAs) to circumvent resistance to ACTs. In this study, we characterized the asexual blood stage antiplasmodial activity and resistance mechanisms of LDT-623, a 4-aminoquinoline (4-AQ). We also detected LDT-623 activity against multiple stages (liver schizonts, stage IV-V gametocytes, and ookinetes) of Plasmodium 's life cycle, a feature unlike other 4-AQs such as chloroquine (CQ) and piperaquine (PPQ). Using heme fractionation profiling and drug uptake studies in PfCRT-containing proteoliposomes, we observed inhibition of hemozoin formation and PfCRT-mediated transport, which constitute characteristic features of 4-AQs' MoA. We also found minimal cross-resistance to LDT-623 in a panel of mutant pfcrt or pfmdr1 lines, but not the PfCRT F145I mutant that is highly resistant to PPQ resistance yet is very unfit. No P. falciparum parasites were recovered in an in vitro resistance selection study, suggesting a high barrier for resistance to emerge. Finally, a competitive growth assay comprising >50 barcoded parasite lines with mutated resistance mediators or major drug targets found no evidence of cross-resistance. Our findings support further exploration of this promising 4-AQ. The emergence of artemisinin-resistant malaria parasites, first in Southeast Asia and more recently East Africa, highlights the urgency to identify and optimize chemotypes with antimalarial activity that are not compromised by known resistance mechanisms in clinical settings. Using a computer-aided drug discovery approach, we previously identified a 4-AQ (LDT-611) that was active against P . falciparum asexual blood-stage (ABS) parasites. Herein, we report the multistage antimalarial activity of a structural analog, a side-chain-modified 4-AQ (LDT-623). This analog shares 4-AQ characteristics, such as PfCRT-mediated transport, as well as inhibition of hemozoin formation, that occurs in the parasite digestive vacuole. Cross-resistance profiling showed that this compound was not compromised by known mutations in the digestive vacuole transporters PfCRT or PfMDR1 or by other gene products that govern resistance to antimalarials under development. Efforts to evolve resistance to LDT-623 in vitro yielded parasite populations lacking noticeable phenotypic changes. In conclusion, we report a 4-AQ whose MoA is likely to differ from licensed antimalarials within this chemical class, paving the way for further studies on this chemotype as a therapeutic avenue to treat multidrug-resistant malaria.

Enhancement of Shelf Life of Button Mushroom, Agaricus bisporus (Higher Basidiomycetes) by Fumigant Application of Lippia alba Essential Oil.

Synthesis, in Vitro and in Vivo Biological Evaluation of Dihydroartemisinin Derivatives with Potential Anti-Toxoplasma Gondii Agents.

Appraisal of Fungus-Derived Xanthoquinodins as Broad-Spectrum Anti-Infectives Targeting Phylogenetically Diverse Human Pathogens

Effects of Infrared‐A Irradiation on Skin: Discrepancies in Published Data Highlight the Need for an Exact Consideration of Physical and Photobiological Laws and Appropriate Experimental Settings

Takeo Ohnishi, PhD, 1944–2017

[Stem cell research using large animals].

[Import of mitochondrial proteins].

Antimalarial activity and mechanisms of action of two novel 4-aminoquinolines against chloroquine-resistant parasites

Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial Activity

Why is natural recovery so common for addictive disorders?

Exploration and Characterization of the Antimalarial Activity of Cyclopropyl Carboxamides that Target the Mitochondrial Protein, Cytochrome b

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Ultrastructural changes in hepatocytes induced by pregnenolone-16a-carbonitrile (PCN).

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-N-oxide derivatives against Giardia lamblia, Trichomonas vaginalis, and Entamoeba histolytica. An in vitro and in silico approach

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

Self-similarity in radial Walsh filters and axial intensity distributions in the far-field diffraction pattern.

Antibacterial Potential of Symmetrical Twin-Drug 3,6-Diaminoxanthones

A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants

Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase

Characterization of the valence transition in YbxIn

Identification of fungal natural products with potent inhibition in Toxoplasma gondii